Download PDF
Horm Metab Res 2008; 40(2): 89-98
DOI: 10.1055/s-2007-1022549
Review

© Georg Thieme Verlag KG Stuttgart · New York

Dendritic Cell Based Immunotherapy - A Promising Therapeutic Approach for Endocrine Malignancies

S. Sbiera 1 , S. Wortmann 1 , M. Fassnacht 1
  • 1Department of Internal Medicine I, Endocrine and Diabetes Unit, University of Wuerzburg, Wuerzburg, Germany
Further Information

Publication History

received 20.09.2007

accepted 23.10.2007

Publication Date:
19 February 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Dendritic cells (DCs) are the most potent antigen presenting cells in the human organism. Ever since the discovery of their function in the self/nonself discrimination, DCs have been seen as potential candidates for therapy in malignant tumors. With the exception of differentiated thyroid cancer, endocrine malignancies are rare tumors and apart from surgical intervention there is no truly established method for their treatment. Therefore, the prognosis of many endocrine carcinomas is still poor and new therapeutic options are needed. In the last decade, different immunotherapeutic approaches have shown promising results in other solid tumors. In recent studies, immunotherapy using DCs has been proven to be safe and effective to induce antitumor immune responses leading to tumor regression and even rejection of cancer in some cases. This review will summarize the latest progress in DCs based immunotherapy with special focus on the limited experience in endocrine malignancies. With regard to these tumors, it is of special interest which antigens could serve as potential target antigens for future trials. We also discuss what steps have to be taken to develop a better immunotherapy in endocrine tumors.

Key words

dendritic cells - immunotherapy - endocrine tumors - adrenocortical carcinoma - thyroid cancer

References

  • 1 Lewis DE, Giorgi JV, Warner NL. Flow cytometry analysis of T cells and continuous T-cell lines from autoimmune MRL/l mice.  Nature. 1981;  289 298-300
    CrossrefPubMedGoogle Scholar
  • 2 Hogan PG, Basten A. What are killer cells and what do they do?.  Blood Rev. 1988;  2 50-58
    CrossrefPubMedGoogle Scholar
  • 3 Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape.  Immunology. 2007;  121 1-14
    CrossrefPubMedGoogle Scholar
  • 4 Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer.  Clin Cancer Res. 2003;  9 4296-4303
    PubMedGoogle Scholar
  • 5 Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.  Int Immunol. 2001;  13 459-463
    CrossrefPubMedGoogle Scholar
  • 6 Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy.  Nat Immunol. 2001;  2 293-299
    PubMedGoogle Scholar
  • 7 Steinman RM. The dendritic cell system and its role in immunogenicity.  Annu Rev Immunol. 1991;  9 271-296
    CrossrefPubMedGoogle Scholar
  • 8 Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells.  Annu Rev Immunol. 2000;  18 767-811
    CrossrefPubMedGoogle Scholar
  • 9 Banchereau J, Steinman RM. Dendritic cells and the control of immunity.  Nature. 1998;  392 245-252
    CrossrefPubMedGoogle Scholar
  • 10 Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy.  Cell. 2001;  106 271-274
    CrossrefPubMedGoogle Scholar
  • 11 Bracho F, Ven C van de, Areman E, Hughes RM, Davenport V, Bradley MB, Cai JW, Cairo MS. A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs.  Cytotherapy. 2003;  5 349-361
    CrossrefPubMedGoogle Scholar
  • 12 Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer.  Nat Rev Immunol. 2005;  5 296-306
    CrossrefPubMedGoogle Scholar
  • 13 Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy.  J Leukoc Biol. 2003;  73 3-29
    CrossrefPubMedGoogle Scholar
  • 14 Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes.  Nat Immunol. 2002;  3 999-1005
    CrossrefPubMedGoogle Scholar
  • 15 Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects.  Nat Rev Immunol. 2004;  4 941-952
    CrossrefPubMedGoogle Scholar
  • 16 Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla.  Horm Metab Res. 2005;  37 717-721
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update.  J Clin Endocrinol Metab. 2006;  91 2027-2037
    CrossrefPubMedGoogle Scholar
  • 18 Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, Heerden JA van, Fernandes JK. Anaplastic thyroid carcinoma: an overview.  Curr Oncol Rep. 2007;  9 152-158
    CrossrefPubMedGoogle Scholar
  • 19 Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: Current treatment of malignant pheochromocytoma.  J Clin Endocrinol Metab. 2007;  92 1217-1225
    CrossrefPubMedGoogle Scholar
  • 20 Rawat N, Khetan N, Williams DW, Baxter JN. Parathyroid carcinoma.  Br J Surg. 2005;  92 1345-1353
    CrossrefPubMedGoogle Scholar
  • 21 Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A, Banchereau J. CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis.  Blood. 1997;  90 1458-1470
    PubMedGoogle Scholar
  • 22 Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood.  Science. 1999;  284 1835-1837
    CrossrefPubMedGoogle Scholar
  • 23 Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.  Nat Med. 1999;  5 919-923
    CrossrefPubMedGoogle Scholar
  • 24 Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L. A novel dendritic cell subset involved in tumor immunosurveillance.  Nat Med. 2006;  12 214-219
    PubMedGoogle Scholar
  • 25 Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, Pardoll DM, Housseau F. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.  Nat Med. 2006;  12 207-213
    PubMedGoogle Scholar
  • 26 Dubsky P, Ueno H, Piqueras B, Connolly J, Banchereau J, Palucka AK. Human dendritic cell subsets for vaccination.  J Clin Immunol. 2005;  25 551-572
    CrossrefPubMedGoogle Scholar
  • 27 Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells.  J Exp Med. 2001;  193 F5-F9
    CrossrefPubMedGoogle Scholar
  • 28 Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?.  Trends Immunol. 2002;  23 445-449
    CrossrefPubMedGoogle Scholar
  • 29 Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.  J Exp Med. 2001;  193 233-238
    CrossrefPubMedGoogle Scholar
  • 30 Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood.  J Exp Med. 1994;  180 83-93
    CrossrefPubMedGoogle Scholar
  • 31 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.  J Exp Med. 1994;  179 1109-1118
    CrossrefPubMedGoogle Scholar
  • 32 Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma.  Curr Opin Immunol. 2001;  13 134-140
    CrossrefPubMedGoogle Scholar
  • 33 Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges G, Palucka AK, Banchereau J. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells.  J Exp Med. 2001;  194 1013-1020
    CrossrefPubMedGoogle Scholar
  • 34 Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.  J Exp Med. 2000;  191 1777-1788
    CrossrefPubMedGoogle Scholar
  • 35 Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.  Blood. 2001;  98 3022-3029
    CrossrefPubMedGoogle Scholar
  • 36 Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+T cell responses against human tumor antigens.  J Immunol. 2004;  172 5363-5370
    PubMedGoogle Scholar
  • 37 Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer.  Curr Opin Immunol. 2005;  17 163-169
    CrossrefPubMedGoogle Scholar
  • 38 Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy.  Curr Opin Immunol. 2003;  15 138-147
    CrossrefPubMedGoogle Scholar
  • 39 Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy.  Trends Immunol. 2001;  22 102-107
    CrossrefPubMedGoogle Scholar
  • 40 Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells.  Immunol Rev. 2004;  199 251-263
    CrossrefPubMedGoogle Scholar
  • 41 Tendeloo VF Van, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Broeckhoven C Van, Bockstaele DR Van, Berneman ZN. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.  Blood. 2001;  98 49-56
    CrossrefPubMedGoogle Scholar
  • 42 Wu TC, Guarnieri FG, Staveley-O’Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.  Proc Natl Acad Sci USA. 1995;  92 11671-11675
    CrossrefPubMedGoogle Scholar
  • 43 Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.  Clin Cancer Res. 2005;  11 5566-5571
    CrossrefPubMedGoogle Scholar
  • 44 Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.  Cancer Treat Rev. 2007;  33 230-283
    CrossrefPubMedGoogle Scholar
  • 45 Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells.  Cancer Immunol Immunother. 2001;  50 3-15
    PubMedGoogle Scholar
  • 46 Parmiani G, Filippo A De, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials.  J Immunol. 2007;  178 1975-1979
    PubMedGoogle Scholar
  • 47 Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update.  Cancer Immunol Immunother. 2005;  54 187-207
    PubMedGoogle Scholar
  • 48 Li G, Ali SA, MacArdle SE, Mian S, Ahmad M, Miles A, Rees RC. Immunity to tumour antigens.  Curr Pharm Des. 2005;  11 3501-3509
    CrossrefPubMedGoogle Scholar
  • 49 Bruggen P van der, Traversari C, Chomez P, Lurquin C, Plaen E de, Eynde B van den, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.  Science. 1991;  254 1643-1647
    CrossrefPubMedGoogle Scholar
  • 50 Traversari C, Bruggen P van der, Luescher IF, Lurquin C, Chomez P, Van Pel A, Plaen E De, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.  J Exp Med. 1992;  176 1453-1457
    CrossrefPubMedGoogle Scholar
  • 51 Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Bruggen P van der. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.  Immunity. 1995;  2 167-175
    CrossrefPubMedGoogle Scholar
  • 52 Eynde B Van den, Peeters O, Backer O De, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.  J Exp Med. 1995;  182 689-698
    CrossrefPubMedGoogle Scholar
  • 53 Plaen E De, Arden K, Traversari C, Gaforio JJ, Szikora JP, Smet C De, Brasseur F, Bruggen P van der, Lethe B, Lurquin C. et al . Structure, chromosomal localization, and expression of 12 genes of the MAGE family.  Immunogenetics. 1994;  40 360-369
    CrossrefPubMedGoogle Scholar
  • 54 Jungbluth AA, Silva  Jr  WA, Iversen K, Frosina D, Zaidi B, Coplan K, Eastlake-Wade SK, Castelli SB, Spagnoli GC, Old LJ, Vogel M. Expression of cancer-testis (CT) antigens in placenta.  Cancer Immun. 2007;  7 15
    PubMedGoogle Scholar
  • 55 Jassim A, Ollier W, Payne A, Biro A, Oliver RT, Festenstein H. Analysis of HLA antigens on germ cells in human semen.  Eur J Immunol. 1989;  19 1215-1220
    CrossrefPubMedGoogle Scholar
  • 56 Blackburn EH. Telomerases.  Annu Rev Biochem. 1992;  61 113-129
    CrossrefPubMedGoogle Scholar
  • 57 Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer.  Science. 1994;  266 2011-2015
    PubMedGoogle Scholar
  • 58 Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin.  J Biol Chem. 2006;  281 33450-33456
    CrossrefPubMedGoogle Scholar
  • 59 Lens SM, Vader G, Medema RH. The case for survivin as mitotic regulator.  Curr Opin Cell Biol. 2006;  18 616-622
    CrossrefPubMedGoogle Scholar
  • 60 Chiou SK, Jones MK, Tarnawski AS. Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond.  Med Sci Monit. 2003;  9 PI25-PI29
    PubMedGoogle Scholar
  • 61 Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions.  J Cell Mol Med. 2005;  9 360-372
    CrossrefPubMedGoogle Scholar
  • 62 Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.  Nat Med. 2000;  6 1011-1017
    PubMedGoogle Scholar
  • 63 Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer.  J Clin Oncol. 2004;  22 2808-2815
    CrossrefPubMedGoogle Scholar
  • 64 Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC, Gabrilovich DI. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.  J Immunother (1997). 2007;  30 169-179
    CrossrefPubMedGoogle Scholar
  • 65 Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy.  Blood. 2003;  102 964-971
    CrossrefPubMedGoogle Scholar
  • 66 Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.  Nat Med. 2002;  8 1369-1375
    PubMedGoogle Scholar
  • 67 LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ, Ferrara N. Identification of an angiogenic mitogen selective for endocrine gland endothelium.  Nature. 2001;  412 877-884
    CrossrefPubMedGoogle Scholar
  • 68 LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis.  Nat Med. 2002;  8 913-917
    PubMedGoogle Scholar
  • 69 Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.  Proc Natl Acad Sci USA. 1994;  91 5657-5661
    CrossrefPubMedGoogle Scholar
  • 70 Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?.  Oncogene. 2004;  23 317-329
    CrossrefPubMedGoogle Scholar
  • 71 Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD. Clinical implications of fibroblast activation protein in patients with colon cancer.  Clin Cancer Res. 2007;  13 1736-1741
    CrossrefPubMedGoogle Scholar
  • 72 Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.  Drug Resist Updat. 2005;  8 51-58
    CrossrefPubMedGoogle Scholar
  • 73 Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer.  Int J Biochem Cell Biol. 2004;  36 408-421
    CrossrefPubMedGoogle Scholar
  • 74 Miescher S, Whiteside TL, Moretta L, Fliedner V von. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.  J Immunol. 1987;  138 4004-4011
    PubMedGoogle Scholar
  • 75 Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion.  Nat Rev Immunol. 2006;  6 715-727
    CrossrefPubMedGoogle Scholar
  • 76 Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity.  Cancer Immunol Immunother. 2005;  54 1153-1161
    PubMedGoogle Scholar
  • 77 Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment.  J Immunother (1997). 2006;  29 233-240
    CrossrefPubMedGoogle Scholar
  • 78 Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.  Cancer Res. 2007;  67 371-380
    CrossrefPubMedGoogle Scholar
  • 79 Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.  Nat Med. 1996;  2 52-58
    PubMedGoogle Scholar
  • 80 Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.  Nat Med. 1998;  4 328-332
    PubMedGoogle Scholar
  • 81 Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M. CD83+blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer.  Lancet. 1998;  352 1358
    PubMedGoogle Scholar
  • 82 Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.  Clin Cancer Res. 1999;  5 1331-1338
    PubMedGoogle Scholar
  • 83 Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.  Cancer Res. 2001;  61 842-847
    PubMedGoogle Scholar
  • 84 Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer.  Cancer Immunol Immunother. 2004;  53 275-306
    PubMedGoogle Scholar
  • 85 Gilboa E. DC-based cancer vaccines.  J Clin Invest. 2007;  117 1195-1203
    CrossrefPubMedGoogle Scholar
  • 86 Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, Driesch P von den, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.  J Exp Med. 1999;  190 1669-1678
    CrossrefPubMedGoogle Scholar
  • 87 Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.  Cancer Res. 2001;  61 6451-6458
    PubMedGoogle Scholar
  • 88 Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, Ueno H, Banchereau J. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.  Cancer Immunol Immunother. 2006;  55 1209-1218
    PubMedGoogle Scholar
  • 89 Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.  J Clin Invest. 2002;  109 409-417
    CrossrefPubMedGoogle Scholar
  • 90 Lesterhuis WJ, Vries IJ de, Adema GJ, Punt CJ. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results.  Ann Oncol. 2004;  15 ((Suppl 4: iv)) 145-151
    PubMedGoogle Scholar
  • 91 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines.  Nat Med. 2004;  10 909-915
    CrossrefPubMedGoogle Scholar
  • 92 Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kampgen E, Schuler G. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.  Ann Oncol. 2006;  17 563-570
    CrossrefPubMedGoogle Scholar
  • 93 Schott M, Feldkamp J, Schattenberg D, Seissler J, Scherbaum WA. Dendritic cell immunotherapy in disseminated parathyroid carcinoma.  Lancet. 1999;  353 1188-1189
    PubMedGoogle Scholar
  • 94 Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA, Seissler J. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma.  Clin Endocrinol (Oxf). 2001;  55 271-277
    CrossrefPubMedGoogle Scholar
  • 95 Schott M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.  Endocr Relat Cancer. 2006;  13 779-795
    CrossrefPubMedGoogle Scholar
  • 96 Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.  J Clin Endocrinol Metab. 2001;  86 4965-4969
    CrossrefPubMedGoogle Scholar
  • 97 Zhang R, DeGroot LJ. A monoclonal antibody against rat calcitonin inhibits the growth of a rat medullary thyroid carcinoma cell line in vitro.  Endocrinology. 1997;  138 1697-1703
    CrossrefPubMedGoogle Scholar
  • 98 Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M. Dendritic cell-based vaccination in solid cancer.  J Clin Oncol. 2003;  21 135-142
    CrossrefPubMedGoogle Scholar
  • 99 Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J. Dendritic cell vaccination in medullary thyroid carcinoma.  Clin Cancer Res. 2004;  10 2944-2953
    CrossrefPubMedGoogle Scholar
  • 100 Schott M, Reincke M, Ortmann D, Bornstein SR. Immunotherapy: new strategies for the treatment of adrenocortical carcinoma.  Horm Metab Res. 2003;  35 451-453
    Article in Thieme ConnectPubMedGoogle Scholar
  • 101 Schott M, Willenberg HS, Papewalis C, Scherbaum WA, Bornstein SR. Dendritic cell vaccination: Potential immunotherapy for adrenocortical carcinoma.  Horm Metab Res. 2004;  36
    PubMedGoogle Scholar
  • 102 Papewalis C, Fassnacht M, Willenberg HS, Domberg J, Fenk R, Rohr UP, Schinner S, Bornstein SR, Scherbaum WA, Schott M. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.  Clin Endocrinol (Oxf). 2006;  65 215-222
    CrossrefPubMedGoogle Scholar
  • 103 Ortmann D, Hausmann J, Beuschlein F, Schmenger K, Stahl M, Geissler M, Reincke M. Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model.  Endocrinology. 2004;  145 1760-1766
    PubMedGoogle Scholar
  • 104 Reincke M, Ortmann D, Hausmann J, Beuschlein F. Cytotoxic T-cell response against steroidogenic acute regulatory protein using DNA vaccination followed by vaccinia virus infection in a mouse adrenal carcinoma model.  Horm Metab Res. 2004;  36 411-414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 105 Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.  Cancer Res. 2005;  65 11156-11163
    CrossrefPubMedGoogle Scholar
  • 106 Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, MacGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.  Cell. 1992;  71 1093-1102
    PubMedGoogle Scholar
  • 107 Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.  Nat Med. 1997;  3 682-685
    CrossrefPubMedGoogle Scholar
  • 108 Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4mAb.  J Immunol. 2000;  164 1230-1235
    PubMedGoogle Scholar
  • 109 Pedersen AE, Buus S, Claesson MH. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.  Cancer Lett. 2006;  235 229-238
    CrossrefPubMedGoogle Scholar
  • 110 Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.  J Immunol. 2005;  175 7746-7754
    PubMedGoogle Scholar
  • 111 Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy.  Nat Immunol. 2002;  3 611-618
    CrossrefPubMedGoogle Scholar
  • 112 Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.  Cancer Res. 2005;  65 1089-1096
    PubMedGoogle Scholar
  • 113 Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O’Dwyer PJ, Running KL, Huhn RD, Antonia SJ. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.  J Clin Oncol. 2007;  25 876-883
    CrossrefPubMedGoogle Scholar
  • 114 Geldart T, Illidge T. Anti-CD 40 monoclonal antibody.  Leuk Lymphoma. 2005;  46 1105-1113
    CrossrefPubMedGoogle Scholar
  • 115 Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership.  Nat Rev Cancer. 2005;  5 397-405
    CrossrefPubMedGoogle Scholar
  • 116 Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.  J Clin Invest. 2006;  116 1955-1962
    CrossrefPubMedGoogle Scholar
  • 117 Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, Scherbaum WA. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells.  Eur J Endocrinol. 2000;  142 300-306
    CrossrefPubMedGoogle Scholar
  • 118 Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma.  Oncol Rep. 2003;  10 1337-1340
    PubMedGoogle Scholar
  • 119 Du ZX, Zhang HY, Gao da X, Wang HQ, Li YJ, Liu GL. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells.  Exp Mol Med. 2006;  38 230-240
    PubMedGoogle Scholar
  • 120 Grabowski P, Griss S, Arnold CN, Horsch D, Goke R, Arnold R, Heine B, Stein H, Zeitz M, Scherubl H. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.  Neuroendocrinology. 2005;  81 1-9
    CrossrefPubMedGoogle Scholar
  • 121 Vikman S, Essand M, Cunningham JL, Torre M de la, Oberg K, Totterman TH, Giandomenico V. Gene expression in midgut carcinoid tumors: potential targets for immunotherapy.  Acta Oncol. 2005;  44 32-40
    PubMedGoogle Scholar
  • 122 Koch CA, Vortmeyer AO, Diallo R, Poremba C, Giordano TJ, Sanders D, Bornstein SR, Chrousos GP, Pacak K. Survivin: a novel neuroendocrine marker for pheochromocytoma.  Eur J Endocrinol. 2002;  146 381-388
    CrossrefPubMedGoogle Scholar
  • 123 Koperek O, Scheuba C, Puri C, Birner P, Haslinger C, Rettig W, Niederle B, Kaserer K, Garin Chesa P. Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma.  Int J Oncol. 2007;  31 59-67
    PubMedGoogle Scholar
  • 124 Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.  Proc Natl Acad Sci USA. 1990;  87 7235-7239
    CrossrefPubMedGoogle Scholar
  • 125 Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S, Leite V. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop.  Eur J Endocrinol. 2005;  153 701-709
    CrossrefPubMedGoogle Scholar
  • 126 Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours.  Histopathology. 1998;  32 133-138
    CrossrefPubMedGoogle Scholar
  • 127 Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y, Nakai T, Okuda Y. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas.  Life Sci. 2004;  74 863-871
    CrossrefPubMedGoogle Scholar
  • 128 Wang SL, Chen WT, Wu MT, Chan HM, Yang SF, Chai CY. Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study.  Endocr Pathol. 2005;  16 211-218
    CrossrefPubMedGoogle Scholar
  • 129 Saji M, Xydas S, Westra WH, Liang CK, Clark DP, Udelsman R, Umbricht CB, Sukumar S, Zeiger MA. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms.  Clin Cancer Res. 1999;  5 1483-1489
    PubMedGoogle Scholar
  • 130 Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H, Miyauchi A. Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.  Oncol Rep. 2007;  18 715-720
    PubMedGoogle Scholar
  • 131 Asaad NY, Abd El-Wahed MM, Mohammed AG. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role.  J Egypt Natl Canc Inst. 2006;  18 8-16
    PubMedGoogle Scholar
  • 132 Luo Z, Li J, Qin Y, Ma Y, Liang X, Xian J, Lu D, Wei M, Yang JY, Yang MQ, He Z. Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.  Endocr Pathol. 2006;  17 387-398
    CrossrefPubMedGoogle Scholar
  • 133 Isobe K, Yashiro T, Omura S, Kaneko M, Kaneko S, Kamma H, Tatsuno I, Takekoshi K, Kawakami Y, Nakai T. Expression of the human telomerase reverse transcriptase in pheochromocytoma and neuroblastoma tissues.  Endocr J. 2004;  51 47-52
    CrossrefPubMedGoogle Scholar
  • 134 Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A, Lehnert H. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.  J Clin Endocrinol Metab. 2003;  88 4280-4286
    CrossrefPubMedGoogle Scholar
  • 135 Zenkert S, Schubert B, Fassnacht M, Beuschlein F, Allolio B, Reincke M. Steroidogenic acute regulatory protein mRNA expression in adrenal tumours.  Eur J Endocrinol. 2000;  142 294-299
    CrossrefPubMedGoogle Scholar
  • 136 Reincke M, Mora P, Beuschlein F, Arlt W, Chrousos GP, Allolio B. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis.  J Clin Endocrinol Metab. 1997;  82 3054-3058
    CrossrefPubMedGoogle Scholar

Correspondence

M. FassnachtMD 

Department of Internal Medicine I

University Hospital Wuerzburg

Jospeh-Schneider Str. 2

97080 Wuerzburg

Germany

Phone: +49/931/201 365 07

Fax: +49/931/201 367 66

Email: fassnacht_m@medizin.uni-wuerzburg.de

      >